The global body fluid collection and diagnostics market size was estimated at USD 36.44 Billion in 2025 and is anticipated to reach USD 61.99 billion by 2033, growing at a CAGR of 6.87% from 2025 to 2033. Rapid results, cost-effectiveness, and early prognosis of diseases are some of the factors contributing to the growth of the body fluid collection and diagnostics industry.
Advances in in-vitro diagnostic techniques are also playing a big role, as they make testing more accurate and efficient, encouraging wider use. For instance, in May 2022, TECHKON GmbH introduced a new method for analyzing body fluids that can assess medical parameters and diagnose diseases at the same time, making testing faster and more comprehensive.
The growing number of blood-related disorders is a key factor driving the demand for blood collection devices. Diseases such as anemia, sickle cell disease, hemophilia, and clotting disorders are becoming more common, along with blood cancers such as myeloma, lymphoma, and leukemia. In the U.S., blood cancer is particularly devastating, taking a life every nine minutes, which adds up to about 157 deaths each day or more than six every hour. In 2023, it’s estimated that nearly 57,380 people in the U.S. will die from leukemia, lymphoma, or myeloma, accounting for almost 9.4% of all cancer-related deaths.
An estimated 437,337 individuals in the U.S. are either living with or in remission from leukemia, while around 879,242 people are in the same condition with lymphoma. Blood clots affect approximately 900,000 Americans each year, leading to about 100,000 deaths annually. Notably, fewer than one in four people show any noticeable signs or symptoms of a blood clot, underscoring the silent but significant impact of this condition.
The growing focus on early disease detection has significantly driven demand in the body fluid collection and diagnostics industry. Samples such as saliva, blood, urine, and semen are increasingly used to analyze biomarkers and other indicators for accurate and timely diagnosis. Moreover, numerous advancements and innovations have been made globally, further enhancing testing capabilities and expanding the range of conditions that can be detected through fluid-based diagnostics. For instance, in July 2021, Abbott announced of launching Panbio COVID-19 Antigen Self-Test in India to strengthen its rapid diagnostics product portfolio. It would support testing needs at work, at clinics, and at home. Further recently, In May 2024, the U.S. FDA approved the Rika Plasma Donation System featuring the iNomi Nomogram developed by Terumo Corporation. This product helps determine plasma collection volume based on an individual donor's weight, height, and hematocrit level at the time of donation.
Alzheimer's Disease (AD) is a severe neurodegenerative disease that requires the identification of precise biomarkers. The development and validation of early-stage biomarkers is a high research priority for existing diagnostics that can detect AD. Body-fluid biomarkers accurately reflect a synaptic failure in the brain and, as a result, could help improve diagnostic accuracy, track the course of the disease, and act as indicators for evaluating the effectiveness of early-onset disease-modifying therapies. In May 2022, the FDA authorized the marketing of a new test that could improve the diagnosis of AD. The Lumipulse test evaluates the ratio of -amyloid 1-40 and-amyloid 1-42 concentrations found in the human cerebral spinal fluid, which can help doctors in determining if a patient is expected to have amyloid plaques, a characteristic symptom of AD.
Body fluid samples contain a large number of naturally occurring biomarker proteins, which effectively show cancer progression. They are also utilized to find these biomarkers in order to validate the presence of cancer. For instance, in January 2022, scientists from the University of Illinois developed a tool that could detect cancer biomarkers in the body fluid samples. The quantification and detection of cancer-associated molecular biomarkers in such body fluids would help for minimally invasive cancer detection.
Furthermore, technological innovations in in-vitro diagnostics, such as high-throughput testing, automation, and integration of AI, have significantly enhanced diagnostic accuracy and efficiency. These advancements enable faster turnaround times and improved sensitivity, making body fluid diagnostic tools indispensable for modern healthcare. The availability of such innovative solutions supports the global adoption of these technologies.
This product will be delivered within 2 business days.
Advances in in-vitro diagnostic techniques are also playing a big role, as they make testing more accurate and efficient, encouraging wider use. For instance, in May 2022, TECHKON GmbH introduced a new method for analyzing body fluids that can assess medical parameters and diagnose diseases at the same time, making testing faster and more comprehensive.
The growing number of blood-related disorders is a key factor driving the demand for blood collection devices. Diseases such as anemia, sickle cell disease, hemophilia, and clotting disorders are becoming more common, along with blood cancers such as myeloma, lymphoma, and leukemia. In the U.S., blood cancer is particularly devastating, taking a life every nine minutes, which adds up to about 157 deaths each day or more than six every hour. In 2023, it’s estimated that nearly 57,380 people in the U.S. will die from leukemia, lymphoma, or myeloma, accounting for almost 9.4% of all cancer-related deaths.
An estimated 437,337 individuals in the U.S. are either living with or in remission from leukemia, while around 879,242 people are in the same condition with lymphoma. Blood clots affect approximately 900,000 Americans each year, leading to about 100,000 deaths annually. Notably, fewer than one in four people show any noticeable signs or symptoms of a blood clot, underscoring the silent but significant impact of this condition.
The growing focus on early disease detection has significantly driven demand in the body fluid collection and diagnostics industry. Samples such as saliva, blood, urine, and semen are increasingly used to analyze biomarkers and other indicators for accurate and timely diagnosis. Moreover, numerous advancements and innovations have been made globally, further enhancing testing capabilities and expanding the range of conditions that can be detected through fluid-based diagnostics. For instance, in July 2021, Abbott announced of launching Panbio COVID-19 Antigen Self-Test in India to strengthen its rapid diagnostics product portfolio. It would support testing needs at work, at clinics, and at home. Further recently, In May 2024, the U.S. FDA approved the Rika Plasma Donation System featuring the iNomi Nomogram developed by Terumo Corporation. This product helps determine plasma collection volume based on an individual donor's weight, height, and hematocrit level at the time of donation.
Alzheimer's Disease (AD) is a severe neurodegenerative disease that requires the identification of precise biomarkers. The development and validation of early-stage biomarkers is a high research priority for existing diagnostics that can detect AD. Body-fluid biomarkers accurately reflect a synaptic failure in the brain and, as a result, could help improve diagnostic accuracy, track the course of the disease, and act as indicators for evaluating the effectiveness of early-onset disease-modifying therapies. In May 2022, the FDA authorized the marketing of a new test that could improve the diagnosis of AD. The Lumipulse test evaluates the ratio of -amyloid 1-40 and-amyloid 1-42 concentrations found in the human cerebral spinal fluid, which can help doctors in determining if a patient is expected to have amyloid plaques, a characteristic symptom of AD.
Body fluid samples contain a large number of naturally occurring biomarker proteins, which effectively show cancer progression. They are also utilized to find these biomarkers in order to validate the presence of cancer. For instance, in January 2022, scientists from the University of Illinois developed a tool that could detect cancer biomarkers in the body fluid samples. The quantification and detection of cancer-associated molecular biomarkers in such body fluids would help for minimally invasive cancer detection.
Furthermore, technological innovations in in-vitro diagnostics, such as high-throughput testing, automation, and integration of AI, have significantly enhanced diagnostic accuracy and efficiency. These advancements enable faster turnaround times and improved sensitivity, making body fluid diagnostic tools indispensable for modern healthcare. The availability of such innovative solutions supports the global adoption of these technologies.
Global Body Fluid Collection And Diagnostics Market Segmentation
This report forecasts revenue growth at global, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, the analyst has segmented the global body fluid collection and diagnostics market report on the basis of sample, technology, application, product and region:Sample Outlook (Revenue, USD Million, 2021-2033)
- Blood
- Saliva
- Urine
- Cerebrospinal Fluid
Product Outlook (Revenue, USD Million, 2021-2033)
- Tests/Services
- Kits & Consumables
- Instruments
Technology Outlook (Revenue, USD Million, 2021-2033)
- Next Generation Sequencing (NGS)
- Polymerase Chain Reaction (PCR)
- Fluorescence in situ hybridization (FISH)
- Others
Application Outlook (Revenue, USD Million, 2021-2033)
- Diagnostics & Monitoring
- Therapeutic Decision Making
- Prognostics & Screening
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segmental and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Body Fluid Collection and Diagnostics Market Variables, Trends & Scope
Chapter 4. Body Fluid Collection and Diagnostics Market: Sample Estimates & Trend Analysis
Chapter 5. Body Fluid Collection and Diagnostics Market: Product Estimates & Trend Analysis
Chapter 6. Body Fluid Collection and Diagnostics Market: Technology Estimates & Trend Analysis
Chapter 7. Body Fluid Collection and Diagnostics Market: Application Estimates & Trend Analysis
Chapter 8. Body Fluid Collection and Diagnostics Market: Regional Estimates & Trend Analysis
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The leading players profiled in this Body Fluid Collection and Diagnostics market report include:- Thermo Fisher Scientific Inc.
- Bio-Rad Laboratories
- Illumina, Inc
- Guardant Health
- QIAGEN
- Johnson & Johnson
- Laboratory Corporation of America Holdings
- Biocept Inc
- F. Hoffmann-La Roche Ltd.
- MDxHealth SA.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 120 |
| Published | September 2025 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 36.44 Billion |
| Forecasted Market Value ( USD | $ 61.99 Billion |
| Compound Annual Growth Rate | 6.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
